Clinical trials: Diabetic Macular Edema
Diabetic Macular Edema
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with…
- Trial name
- REEF (NCT01292798)
- Testing
- Ranibizumab
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- California Retina Consultants
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema
The objective of this study is to investigate the safety and efficacy of minocycline as a microglia inhibitor in individuals with diabetic macular edema (DME).
- Trial name
- NCT01120899
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Retinopathy, Diabetic Macular Edema
PROMINENT-Eye Ancillary Study (Protocol AD)
Despite improved glycemic and systemic control for many patients with diabetes, over the past several decades, diabetic retinopathy (DR) develops and progresses in a large proportion of patients, and visual loss from diabetic eye…
- Trial name
- NCT03345901
- Testing
- Pemafibrate
- Where
- 71 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME.
- Trial name
- NCT02363621
- Testing
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration
SD-OCT Angiography
The objective of this study is to image retinal vascular alterations in patients with retinal disease using the AngioVue OCT-A system and understand the information these images provide.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- NCT02510885
- Testing
- AngioVue SD-OCT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Diabetic Macular Edema
A Study to Evaluate the Safety and Tolerability of EXN407
This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved…
- Trial name
- NCT04565756
- Testing
- EXN407
- Where
- 11 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Exonate Limited
DIABETIC MACULAR EDEMA
Triamcinolone vs. Laser for Diabetic Macular Edema
The purpose of this study is to determine if intravitreal triamcinolone acetonide (IVTA) injection at the time of cataract surgery will improve visual acuity and decrease post-operative swelling in diabetic patients requiring…
- Trial name
- IVTA (NCT00229931)
- Testing
- Triamcinolone acetonide, laser
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Oklahoma
Diabetic Macular Edema
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
- Trial name
- NCT02914613
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment.
- Trial name
- LRTforDME+PRP (NCT00445003)
- Testing
- Ranibizumab, Triamcinolone Acetonide, Focal/grid laser
- Where
- 56 sites in United States
- Volunteers
- 333 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME).
- Trial name
- DA VINCI (NCT00789477)
- Testing
- Laser Photocoagulation, Intravitreal Aflibercept Injection
- Where
- 47 sites in United States, Austria and 1 more
- Volunteers
- 221 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Diabetic Macular Edema
Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema
The investigators hypothesize that a combination treatment with Avastin and Ozurdex will result in a more rapid improvement of visual acuity compared to the use of Avastin alone.
- Trial name
- NCT01309451
- Testing
- Bevacizumab, dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Retinal Disease
Assessment of Novel Intraocular Injection Guide
To determine if a novel intraocular injection guide (IIG) reduces patient discomfort during and after intravitreal injections.
- Trial name
- NCT02315170
- Testing
- intraocular injection guide, standard lid speculum
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Diabetic Retinopathy
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative…
- Trial name
- ROBIN (NCT03238963)
- Testing
- BI 1467335
- Where
- 35 sites in United States, Austria and 6 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W)…
- Trial name
- RHINE (NCT03622593)
- Testing
- Aflibercept, Faricimab
- Where
- 188 sites in United States, Argentina and 22 more
- Volunteers
- 951 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema
This study is an interventional, prospective randomized study comparing the dexamethasone implant to intravitreal aflibercept. Subjects will have an initial single injection of aflibercept and will be randomized if diabetic…
- Trial name
- PRECISION (NCT04411693)
- Testing
- Dexamethasone implant, Aflibercept
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Diabetic Macular Edema
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered…
- Trial name
- NCT05151731
- Testing
- Vamikibart, Ranibizumab
- Where
- 74 sites in United States, Argentina and 7 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy, Diabetic Macular Edema
Bangladesh PRODUCTIVity in Eyecare Trial
The purpose of this study is to assess the impact of using autonomous artificial intelligence (AI) system for identification of diabetic retinopathy (DR) and diabetic macular edema on productivity of retina specialists in…
- Trial name
- B-PRODUCTIVE (NCT05182580)
- Testing
- Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema
- Where
- Bangladesh
- Volunteers
- 993 people, healthy volunteers welcome
- Sponsor
- Orbis